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Abstract
Background: Management and choice of sedation is important during critical illness in order to reduce patient
suffering and to facilitate the delivery of care. Unfortunately, medications traditionally used for sedation in the
intensive care unit (ICU) such as benzodiazepines and propofol are associated with significant unwanted effects.
Clonidine is an alpha-2 selective adrenergic agonist that may have a role in optimizing current sedation practices in
the pediatric and adult critically ill populations by potentially minimizing exposure to other sedative agents.
Methods/design: We will search MEDLINE, EMBASE, CINAHL, ACPJC, the Cochrane trial registry, World Health
Organization International Clinical Trials Registry Platform (WHO ICTRP), and clinicaltrials.gov for eligible
observational studies and randomized controlled trials investigating the use of clonidine as an adjunctive or
stand-alone sedative agent in patients requiring invasive mechanical ventilation. Our primary outcome is the
duration of mechanical ventilation. Secondary outcomes include the following, listed by priority: duration of
sedation infusions, dose of sedation used, level of sedation, incidence of withdrawal from other sedatives,
delirium incidence, ICU and hospital length of stay, use and duration of non-invasive ventilation, and all-cause
ICU and hospital mortality. We will also capture unwanted effects potentially associated with clonidine
administration such as clinically significant hypotension or bradycardia, clonidine withdrawal, self-extubation,
and the accidental removal of central intravenous lines and arterial lines.
We will not apply any publication date, language, or journal restrictions. Two reviewers will independently
screen and identify eligible studies using predefined eligibility criteria and then review full reports of all
potentially relevant citations. A third reviewer will resolve disagreements if consensus cannot be achieved.
We will use Review Manager (RevMan) to pool effect estimates from included studies across outcomes. We
will present the results as relative risk (RR) with 95 % confidence intervals (CI) for dichotomous outcomes and
as mean difference (MD) or standardized mean difference (SMD) for continuous outcomes with 95 % CI. We
will assess the quality of evidence using the Grading of Recommendations, Assessment, Development and
Evaluation (GRADE) approach.
Discussion: The aim of this systematic review is to summarize the evidence on the efficacy and safety of
clonidine as a sedative agent in the critically ill population.
Systematic review registration: PROSPERO CRD42015019365.
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Background
Description of the condition
The use of sedative agents in the mechanically ventilated,
critically ill population is well established, and the ration-
ale for their use is multifaceted. Sedation is important in
reducing patient discomfort and suffering through allevi-
ation of pain and anxiety [1]. Sedation also reduces the
autonomic hyperactivity that frequently results when these
factors are poorly controlled [2]. Achieving appropriate
levels of sedation also facilitates the delivery of care and
enhances patient safety by reducing the risks of accidental
removal of life-sustaining interventions such as endo-
tracheal tubes or central venous catheters [3].
Despite the benefits of sedation, oversedation is unfavor-
able, as it minimizes patient interaction with caregivers
and family members, delays weaning from the ventilator,
may influence risk of delirium, and unnecessarily prolongs
intensive care unit (ICU) stay [4]. The optimal sedation
regimen should therefore provide adequate sedation with
a rapid onset, allow timely recovery after cessation with
minimal drug accumulation, lead to minimal adverse
effects, and be relatively inexpensive. As a result, guide-
lines recommend the minimization of intravenous sed-
ation infusions and the use of as small doses of sedatives
as possible [5].
Commonly used and widely available ICU sedative
agents include propofol and benzodiazepines (such as lor-
azepam, midazolam, and diazepam) [5–7]. These sedative
agents are frequently used in conjunction with analgesic
medications, such as opioids [8].
Importantly, the use of these sedative agents is not with-
out adverse effects. Propofol is known to cause hypotension
in a significant number of patients [9]. Propofol infusion
syndrome, although a rare complication associated with
higher doses and a longer duration of treatment, manifests
with arrhythmias, rhabdomyolysis, acute kidney injury,
myocardial dysfunction and is associated with a very high
mortality rate [10]. Benzodiazepines may cause respiratory
and cardiovascular depression as well as unintended exces-
sive sedation secondary to drug accumulation in adipose
tissue [11]. Benzodiazepines have also been shown to be
associated with increased rates of ICU delirium and
prolonged mechanical ventilation compared to other non-
benzodiazepine sedative agents [12].
Dexmedetomidine is a centrally acting alpha-2 agonist
that has sedative properties. Although smaller trials have
shown that it may reduce the duration of mechanical
ventilation and delirium with a decrease need for alter-
native sedatives [13–15], it is not universally available
mostly related to cost.
Description of intervention
Clonidine is a centrally acting alpha-2 selective adrener-
gic agonist similar in action to dexmedetomidine.
Traditionally, clonidine has been used to treat attention
deficit hyperactivity disorder (ADHD) [16], opioid and
alcohol withdrawal [17, 18], hypertension, vasomotor
menopausal symptoms, and for neuraxial anesthesia via
epidural administration [19, 20]. In the critically ill
pediatric population, clonidine is frequently used as a
sedative agent, particularly as an adjunctive agent when
there is an inadequate response to opioids and benzodi-
azepines, or to help facilitate weaning from mechanical
ventilation [21]. The evidence to support the use of clo-
nidine in the critically ill adult population is less clear.
Overall, the current clinical use of clonidine in the critic-
ally ill is quite variable [4].
Data supporting the use of clonidine as a sedative agent
in the ICU setting remains limited. Known side effects of
clonidine include hypotension and rarely bradycardia, as
well as rebound tachycardia and hypertension after cloni-
dine withdrawal. Clonidine can be administered via oral,
transdermal, or intravenous route. However, only the oral
and transdermal formulations are available in North
America. Generic versions of clonidine are available, mak-
ing this intervention extremely inexpensive.
How the intervention might work
Clonidine is a centrally acting alpha-2 selective adrener-
gic agonist. It has been postulated that clonidine exerts
its sedative effects via stimulation of the pre-synaptic
alpha-2 adrenoceptors of the locus coeruleus, decreasing
norepinephrine release [22]. Clonidine also has action
on the cholinergic, purinergic, and serotonergic path-
ways, resulting in analgesia [22].
Why it is important to do this review
The current literature on sedation practices in the critic-
ally ill patient population lacks comprehensive summary
data on the efficacy of clonidine as a sedative agent. One
systematic review, which focused only on pediatric ICU
patients, found that adjunctive clonidine use decreased
the requirement for other sedative agents, decreased
withdrawal symptoms when weaning off benzodiaze-
pines and/or opiates, and was associated with minimal
clinically significant adverse effects [21]. Another sys-
tematic review specifically examined the role of alpha-2
agonists on sedation in the mechanically ventilated pa-
tient population, however focused only on the role of
dexmedetomidine [23].
Clonidine is an attractive alternative to other sedating
medications given its ease of administration and its
improved safety profile. Despite the potential concern re-
garding hypotension in comparison to dexmedetomidine,
clonidine is associated with significant advantages includ-
ing the availability of an oral formulation and significant
cost savings.
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Objectives
We plan to conduct a systematic review of all observa-
tional studies, quasi-experimental studies, and RCTs that
investigated the use of clonidine as an adjunctive or
stand-alone sedative agent in the critically ill population.
Methods/design
Types of studies
We plan to include all observational cohort studies that
included a control or comparator arm, quasi-experimental
studies, and RCTs reporting the use of clonidine as a seda-
tive agent in mechanically ventilated patients. We will
exclude case reports, case series, or observational studies
that did not include a control/comparator. We will impose
no methodological quality restrictions.
Types of participants
The population of interest includes all patients, including
children (under 18 years of age) and adults (18 years of age
or older) who require invasive mechanical ventilation
(IMV) and sedation. We will exclude studies enrolling
exclusively neonates or those that take place exclusively in
the neonatal intensive care unit (NICU). If a study includes
both IMV and non-invasive ventilation (NIV) patients, we
will include the study, but exclude all NIV patients if
possible.
Types of interventions
The intervention of interest is the use of clonidine as a
sedative agent for more than 24 h. We will include any
mode of delivery of clonidine other than intrathecal. We
require the studies to have used clonidine either as an
adjunctive or as a stand-alone sedative agent. The com-
parators or control group will be any standard sedation
regimen that does not include clonidine, such as propofol,
benzodiazepines, dexmedetomidine, and/or opioids. We
will exclude studies using clonidine as a pre-medication
for anesthesia or studies in which patients were given clo-
nidine for an alternate indication.
Types of outcome measures
Our primary outcome is the duration of mechanical venti-
lation. Secondary outcomes include the following, listed
by priority: duration of sedation infusions, dose of sed-
ation used, level of sedation (as assessed by standardized
sedation scores such as the Richmond Agitation-Sedation
Scale or COMFORT score), incidence of withdrawal from
other sedatives, delirium incidence (using the Confusion
Assessment Method for the Intensive Care Unit (CAM-
ICU), ICU and hospital length of stay, use and duration of
NIV, and all-cause ICU and hospital mortality. We will
also capture unwanted effects potentially associated with
clonidine administration such as clinically significant
hypotension or bradycardia (with end-organ dysfunction
or requiring intervention), clonidine withdrawal (rebound
tachycardia or hypertension), self-extubation, and the acci-
dental removal of central intravenous lines and arterial
lines. We will also capture unwanted effects such as clinic-
ally significant hypotension or bradycardia (with end-
organ dysfunction or requiring intervention), clonidine
withdrawal (rebound tachycardia or hypertension), self-
extubation, and the accidental removal of central intraven-
ous lines and arterial lines.
Search methods for identification of studies
We will search the following electronic databases: MED-
LINE, EMBASE, ACPJC, CINAHL, and the Cochrane trial
registry for eligible articles with no date or language re-
striction. See appendix for MEDLINE search strategy
[Additional file 1]. Keyword search terms include cloni-
dine, sedation, critically ill, mechanical ventilation, delir-
ium, and withdrawal.
Searching other resources
Two reviewers will independently hand-search the refer-
ences of review articles and systematic reviews on the
same topic for eligible articles. In addition, we will
search for unpublished or ongoing trials on the WHO
International Clinical Trials Registry (WHO ICTRP),
current controlled trials metaregister of controlled trials,
clinicaltrials.gov database, and conference proceedings cit-
ation index within the last 2 years for the Society of
Critical Care Medicine (SCCM), Canadian Critical Care
Society, the European Society of Intensive Care Medicine
(ESICM), the International Society of Intensive Care and
Emergency Medicine (ISICEM), American Thoracic
Society (ATS), and the World Federation of Pediatric
Intensive and Critical Care Societies.
Data collection and analysis
After identification of potentially relevant articles, three
reviewers (JW, EBC, BR) working in pairs will independ-
ently screen all citations and references using specific
eligibility criteria. Disagreements will be resolved by
discussion and consensus with the help of the third
reviewer if needed.
Data extraction and management
Data extraction will be done independently and in
duplicate using pre-designed data abstraction forms
(see “Observational abstraction [Additional file 2]” and
“RCT abstraction” [Additional file 3]). Abstracted data
will include the study title, first author, relevant demo-
graphic data, intervention and control, results for out-
comes of interest, and information on the
methodological quality for each study. A third reviewer
will resolve inconsistent data extraction between the
two reviewers.
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Assessment of risk of bias in included studies
Two reviewers will independently assess the risk of bias
for each included study using the Cochrane Collaboration
tool for assessing risk of bias [24] for RCTs and the
Ottawa-Newcastle tool for observational studies [25]. Risk
of bias assessment will be performed individually per out-
come. A third reviewer will be available to resolve any dis-
agreements. For each study, a description for each domain
assessed will be included along with comments if neces-
sary and a final judgment. The risk of bias for each study
will be categorized as follows: (1) low risk of bias, where
bias is not present or if present, unlikely to affect out-
comes, (2) high risk of bias, where outcomes are likely to
be significantly affected by bias, (3) unclear risk of bias,
where there is inadequate reported information to prop-
erly assess bias or where it is unclear how much the risk
of bias may affect outcomes.
RCTs will be assessed for adequate sequence generation,
allocation sequence concealment, blinding, selective out-
come reporting, and other bias. Sequence generation will
be considered adequate if the study explicitly described an
appropriate randomization procedure to generate an un-
predictable sequence of allocation, including computer-
ized randomization, use of random number tables, and
coin tossing. Concealment of allocation will be considered
adequate if specific methods to protect allocation were
documented and implemented. Performance bias will be
considered low if a study reported participant, caregiver,
and/or researcher blinding. Blinding of outcome assess-
ment will be considered adequate if outcome assessors
and adjudicators were blinded. Within-study selective
reporting of outcomes will be examined by reviewing the
a priori study protocol if available. If the study protocol is
not available, we will compare the outcomes listed in the
“Methods/design” section with those reported in the
manuscript.
Observational studies will be assessed for the follow-
ing: representativeness of the exposed cohort, selection
of the non-exposed cohort, ascertainment of exposure,
demonstration that the outcome of interest was not
present at the start of the study, the comparability of the
cohorts on the basis of the design or analysis, outcome
assessment methods, and the adequacy of follow-up.
Measures of treatment effect
When pooling of outcome data is appropriate, RevMan
5.2 software will be used to conduct meta-analyses.
RCTs and observational studies will be pooled and ana-
lyzed separately. We will use the method of DerSimonian
and Liard in random effects model to pool effect sizes for
each outcome; study weights will be measured using the
inverse variance method. We will present the results as
relative risk (RR) with 95 % confidence interval (CI) for di-
chotomous outcomes and as mean difference (MD) or
standardized mean difference (SMD) for continuous out-
comes with 95 % CI. We plan to perform random effects
analysis for all outcomes of interest. If significant unex-
plained heterogeneity exists, or if there is an insufficient
number of RCTs for meta-analyses, data will be described
qualitatively. The number needed to treat (NNT) with
95 % CI will be derived from pooled risk ratios and its
95 % CI utilizing assumed control risk (ACR) for each out-
come similar to the approach recommended by the
Cochrane collaboration:NNT = 1/[ACR × (1 − RR)] [26].
Dealing with missing data
Where possible, if missing data is encountered, we will
attempt to contact the individual study authors for add-
itional information. If this is not possible, we will analyze
the available data and report any potential impact of
missing data on the results in the “Discussion” section.
Assessment of heterogeneity
We will assess for heterogeneity between studies using
the chi-squared test for homogeneity, where p < 0.01 in-
dicates substantial heterogeneity, and the I2 statistic. We
consider I2 > 50 % to be significant heterogeneity, which
will be further investigated with subgroup analyses to as-
sess clinical and methodological sources of heterogeneity
in intervention effect. If there is significant statistical or
clinical heterogeneity not explained by subgroup or sen-
sitivity analyses, we will not perform a meta-analysis,
and instead, we will describe the data qualitatively.
Assessment of reporting biases
We will look for potential publication bias using a funnel
plot if greater than ten trials are included. For continu-
ous outcomes, the Egger test [24] will be used to detect
funnel plot asymmetry. For dichotomous outcomes, the
arcsine test will be used. All analyses will be performed
using RevMan or R.
Subgroup analysis and investigation of heterogeneity
Potential and expected clinical sources of heterogeneity
include different patient demographics, dosing strategies
and delivery of clonidine, non-clonidine sedative regi-
mens, and different methods of capture for certain out-
comes such as delirium or level of sedation.
To explore significant heterogeneity, when possible,
we will conduct the following subgroup analyses: (1)
children (under 18 years of age), hypothesizing that the
adult population may benefit more from clonidine, given
an increased prevalence of opioid or alcohol withdrawal.
(2) Clonidine delivered via enteral vs. parenteral route,
hypothesizing that there may be issues with enteral
delivery of clonidine in the critically ill due to access (for
example, requiring a nasogastric tube), absorption, or
tolerance concerns leading to greater benefit with
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parenteral delivery. (3) Clonidine delivered once or twice
per day vs. more frequent dosing, hypothesizing that the
more frequent dosing regimen would provide a more
predictable and steady concentration of the drug. (4)
Early administration (within the first 48 h following in-
tubation) vs. later administration (after the first 48 h fol-
lowing intubation), hypothesizing that earlier use will
facilitate weaning or prevent features of withdrawal. (5)
Patients who have ongoing opioid or alcohol use leading
to a high risk for withdrawal vs. patients without a his-
tory of opioid or alcohol use, hypothesizing that with-
drawal patients may benefit more from clonidine. (6)
Unclear or high risk of bias studies vs. low risk of bias
studies, hypothesizing that the studies at high risk of
bias will show a larger effect size.
We acknowledge that subgroup analysis may not be
possible depending on the number of trials included in
the final analysis.
Sensitivity analysis
A priori sensitivity analysis will be performed excluding
studies only reported as abstracts and lacking formal
publication. Post hoc sensitivity analysis will be per-
formed where appropriate.
Assessing the quality of evidence
The Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach will
be used to assess the quality of evidence for each
outcome [27]. The GRADE system classifies the qual-
ity of the aggregate body of evidence as high, moder-
ate, low, or very low. The evidence will be evaluated
using the following criteria: (1) study design and
rigor of its execution (i.e., individual study risk of
bias), (2) the extent to which the evidence could be
applied to patients of interest (i.e., directness), (3)
the consistency of results, (4) the analysis of the re-
sults (i.e., precision), and (5) whether there was a
likelihood of publication bias. The following three
factors lead to potential upgrading of the quality of
evidence if present: (1) a strong or very strong asso-
ciation between an intervention and the observation
of interest, (2) a highly statistically significant rela-
tionship between dose and effect, and (3) a plausible
confounding variable that could explain a reduced
effect or could explain an effect if one was not
anticipated.
A final overall quality of evidence will be summarized
for the intervention taking into consideration both desir-
able and undesirable outcomes. An evidence profile will
be included in the results showing the GRADE assess-
ments and pooled analysis per outcome.
Discussion
The ideal sedative agent allows for safe and effective sed-
ation practices, thereby potentially reducing the time re-
quired to wean from invasive mechanical ventilation and
minimizing the use of other sedative-analgesic agents. It
should also be associated with minimal adverse effects. Al-
though no perfect agent exists, clonidine may be beneficial
compared to available alternatives. This systematic review
will summarize the evidence on the efficacy and safety of
using clonidine as a sedative agent in critically ill patients.
The quality of evidence will be assessed using the GRADE
approach to characterize the confidence in the estimate of
effect.
Additional files
Additional file 1: An outline of our search strategy. (XLSX 30 kb)
Additional file 2: Observational studies data abstraction form.
(DOCX 75 kb)
Additional file 3: RCT data abstraction form. (XLSX 26 kb)
Abbreviations
ACPJC: American College of Physicians Journal Club; ACR: assumed control
risk; ADHD: attention deficit hyperactivity disorder; ATS: American Thoracic
Society; CAM-ICU: Confusion Assessment Method for the Intensive Care Unit;
CI: confidence interval; CINAHL: Cumulative Index to Nursing and Allied
Health Literature; ESICM: European Society of Intensive Care Medicine;
GRADE: Grading of recommendations assessment development and
evaluation; ICU: intensive care unit; IMV: invasive mechanical ventilation;
ISICEM: International Society of Intensive Care and Emergency Medicine;
MD: mean difference; NICU: neonatal intensive care unit; NIV: non-invasive
ventilation; NNT: number needed to treat; RCT: randomized controlled trial;
RR: relative risk; SCCM: Society of Critical Care Medicine; SMD: standardized
mean difference; WHO ICTRP: World Health Organization International
Clinical Trials Registry Platform.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BR conceived the idea. JW, EB, and BR designed the search strategy and data
abstraction forms. JW, EB, BR, LB, MD, TK, DP, HW, FD, and WA participated in
the design of the protocol and contributed to drafting the manuscript. All
authors have read and approved the final manuscript.
Acknowledgements
We would like to express our gratitude to Jean Maragno and Lois Cottrel for
their guidance in designing and carrying out our search strategy.
Funding
There is no dedicated funding for this project.
Author details
1Department of Medicine, Faculty of Health Sciences, McMaster University,
Hamilton, Ontario, Canada. 2Department of Clinical Epidemiology and
Biostatistics, McMaster University, Hamilton, Ontario, Canada. 3Department of
Pharmacy, Mount Sinai Hospital, Toronto, Ontario, Canada. 4Leslie Dan
Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
5Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
6Hamilton Health Sciences, Hamilton, Ontario, Canada. 7St. Joseph’s
Healthcare Hamilton, Hamilton, Ontario, Canada. 8Department of Critical Care
Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
9Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada.
10Interdepartmental Division of Critical Care Medicine, University of Toronto,
Toronto, Ontario, Canada.
Jing Wang et al. Systematic Reviews  (2015) 4:154 Page 5 of 6
Received: 8 July 2015 Accepted: 19 October 2015
References
1. Mazzeo AJ. Sedation for the mechanically ventilated patient. Crit Care Clin.
1995;11(4):937.
2. Lewis KS, Whipple JK, Michael KA, Quebbeman EJ. Effect of analgesic
treatment on the physiological consequences of acute pain. Am J Health
Syst Pharm. 1994;51(12):1539–54.
3. Hansen-Flaschen J. Improving patient tolerance of mechanical ventilation.
Challenges ahead. Crit Care Clin. 1994;10(4):659–71.
4. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative
infusions in critically ill patients undergoing mechanical ventilation. N Engl J
Med. 2000;342(20):1471–7.
5. Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice
guidelines for the management of pain, agitation, and delirium in adult
patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
6. Wunsch H, Kahn JM, Kramer AA, Rubenfeld GD. Use of intravenous infusion
sedation among mechanically ventilated patients in the United States*. Crit
Care Med. 2009;37(12):3031–9.
7. Gerlach AT, Murphy CV, Dasta JF. An updated focused review of
dexmedetomidine in adults. Ann Pharmacother. 2009;43(12):2064–74.
http://dx.doi.org/10.1345/aph.1M310.
8. Kress JP, Hall JB. Sedation in the mechanically ventilated patient. Crit Care
Med. 2006;34(10):2541–6.
9. Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a
review of its clinical efficacy in intensive care sedation. Drugs.
1995;50(4):636–57.
10. Kam P, Cardone D. Propofol infusion syndrome. Anaesthesia.
2007;62(7):690–701.
11. Kollef MH, Levy NT, Ahrens TS, Schaiff R, Prentice D, Sherman G. The use of
continuous iv sedation is associated with prolongation of mechanical
ventilation. CHEST Journal. 1998;114(2):541–8.
12. Ostermann ME, Keenan SP, Seiferling RA, Sibbald WJ. Sedation in the
intensive care unit: a systematic review. JAMA. 2000;283(11):1451–9.
13. Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, et al.
Dexmedetomidine vs midazolam or propofol for sedation during prolonged
mechanical ventilation: two randomized controlled trials. JAMA.
2012;307(11):1151–60.
14. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al.
Dexmedetomidine vs midazolam for sedation of critically ill patients: a
randomized trial. JAMA. 2009;301(5):489–99.
15. Venn R, Bradshaw C, Spencer R, Brealey D, Caudwell E, Naughton C, et al.
Preliminary UK experience of dexmedetomidine, a novel agent for
postoperative sedation in the intensive care unit. Anaesthesia.
1999;54(12):1136–42.
16. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to
psychostimulant medication for hyperactive and aggressive children.
Journal of the American Academy of Child & Adolescent Psychiatry.
2003;42(8):886–94.
17. Gold M, Redmond DE, Kleber H. Clonidine blocks acute opiate-withdrawal
symptoms. Lancet. 1978;312(8090):599–602.
18. Baumgartner G, Rowen R. Transdermal clonidine versus chlordiazepoxide in
alcohol withdrawal: a randomized, controlled clinical trial. South Med J.
1991;84(3):312–21.
19. Wallet F, Clement HJ, Bouret C, Lopez F, Broisin F, Pignal C, et al. Effects of a
continuous low-dose clonidine epidural regimen on pain, satisfaction and
adverse events during labour: a randomized, double-blind, placebo-
controlled trial. European Journal of Anaesthesiology (EJA). 2010;27(5):441–7.
20. Rauck RL, Eisenach JC, Jackson K, Young L, Southern J. Epidural clonidine
treatment for refractory reflex sympathetic dystrophy. Anesthesiology.
1993;79(6):1163–9. discussion 27A.
21. Duffett M, Koop A, Menon K, Meade MO, Cook DJ. Clonidine for the
sedation of critically ill children: a systematic review. Journal of Pediatric
Intensive Care. 2012;1(1):5–15.
22. Jamadarkhana S, Gopal S. Clonidine in adults as a sedative agent in the
intensive care unit. J Anaesthesiol Clin Pharmacol. 2010;26(4):439.
23. Chen K, Lu Z, Xin YC, Cai Y, Chen Y, Pan SM. Alpha-2 agonists for
long-term sedation during mechanical ventilation in critically ill patients.
The Cochrane database of systematic reviews. 2015;1:CD010269.
doi:10.1002/14651858.CD010269.pub2.
24. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The
Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.
BMJ. 2011;343:d5928.
25. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and
susceptibility to bias in observational studies in epidemiology: a systematic
review and annotated bibliography. Int J Epidemiol. 2007;36(3):666–76.
26. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
et al. GRADE: an emerging consensus on rating quality of evidence
and strength of recommendations. BMJ. 2008;336(7650):924–6.
doi:10.1136/bmj.39489.470347.AD.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jing Wang et al. Systematic Reviews  (2015) 4:154 Page 6 of 6
